Avanza Fonder Ab Autolus Therapeutics PLC Transaction History
Avanza Fonder Ab
- $3.38 Trillion
- Q2 2025
A detailed history of Avanza Fonder Ab transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Avanza Fonder Ab holds 53,522 shares of AUTL stock, worth $125,776. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,522
Previous 21,276
151.56%
Holding current value
$125,776
Previous $33.4 Million
265.33%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding AUTL
# of Institutions
96Shares Held
160MCall Options Held
0Put Options Held
88.3K-
Wellington Management Group LLP Boston, MA27.1MShares$63.7 Million0.01% of portfolio
-
Blackstone Inc New York, NY20.5MShares$48.1 Million0.14% of portfolio
-
Deep Track Capital, LP Greenwich, CT17.8MShares$41.9 Million0.97% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$39.1 Million98.24% of portfolio
-
Armistice Capital, LLC New York, NY11MShares$25.9 Million0.26% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $214M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...